Balentine LLC Buys Shares of 1,072 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Balentine LLC purchased a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 1,072 shares of the biopharmaceutical company's stock, valued at approximately $680,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Pinney & Scofield Inc. bought a new position in shares of Regeneron Pharmaceuticals in the 4th quarter worth approximately $25,000. E Fund Management Hong Kong Co. Ltd. raised its position in shares of Regeneron Pharmaceuticals by 344.4% in the 1st quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock worth $25,000 after acquiring an additional 31 shares in the last quarter. Crowley Wealth Management Inc. bought a new position in shares of Regeneron Pharmaceuticals in the 4th quarter worth approximately $36,000. Tompkins Financial Corp bought a new position in shares of Regeneron Pharmaceuticals in the 1st quarter worth approximately $32,000. Finally, Curat Global LLC bought a new position in shares of Regeneron Pharmaceuticals in the 1st quarter worth approximately $32,000. Institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Price Performance

Shares of REGN stock traded down $7.48 during trading hours on Friday, hitting $542.52. The stock had a trading volume of 1,307,803 shares, compared to its average volume of 929,805. Regeneron Pharmaceuticals, Inc. has a one year low of $476.49 and a one year high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.93 and a quick ratio of 4.03. The stock's 50-day moving average price is $544.44 and its two-hundred day moving average price is $614.99. The stock has a market capitalization of $58.57 billion, a price-to-earnings ratio of 13.81, a PEG ratio of 2.01 and a beta of 0.33.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share for the quarter, missing the consensus estimate of $8.83 by ($0.61). Regeneron Pharmaceuticals had a return on equity of 15.27% and a net margin of 31.94%. The company had revenue of $3.03 billion for the quarter, compared to the consensus estimate of $3.40 billion. During the same period in the previous year, the firm earned $9.55 earnings per share. The company's revenue was down 3.7% compared to the same quarter last year. Equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, June 6th. Shareholders of record on Tuesday, May 20th were given a dividend of $0.88 per share. The ex-dividend date was Tuesday, May 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.65%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 8.96%.

Wall Street Analyst Weigh In

Several research firms recently weighed in on REGN. Truist Financial cut their price target on Regeneron Pharmaceuticals from $975.00 to $940.00 and set a "buy" rating on the stock in a research note on Wednesday, April 30th. Royal Bank Of Canada downgraded Regeneron Pharmaceuticals from a "moderate buy" rating to a "hold" rating and set a $662.00 price target on the stock. in a research note on Friday, May 30th. Guggenheim restated a "buy" rating on shares of Regeneron Pharmaceuticals in a research note on Friday, May 30th. Wells Fargo & Company downgraded Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and cut their price target for the stock from $700.00 to $580.00 in a research note on Friday, May 30th. Finally, Robert W. Baird cut their target price on Regeneron Pharmaceuticals from $759.00 to $652.00 and set a "neutral" rating on the stock in a research note on Friday, April 25th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating, sixteen have given a buy rating and three have assigned a strong buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $823.54.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.